Section Arrow
EWTX.NASDAQ
- Edgewise Therapeutics
Quotes are at least 15-min delayed:2026/04/21 18:16 EDT
After Hours
Last
 32.45
0 (0.00%)
Bid
31.75
Ask
35.3
High 32.45 
Low 32.45 
Volume 37.40K 
Regular Hours (Closed)
Last
 32.45
-1.52 (-4.47%)
Day High 
34.115 
Prev. Close
33.97 
1-M High
35 
Volume 
711.23K 
Bid
31.75
Ask
35.3
Day Low
32.09 
Open
33.95 
1-M Low
28.9 
Market Cap 
3.64B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 33.41 
20-SMA 32.5 
50-SMA 30.86 
52-W High 35 
52-W Low 12.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.63/-2.90
Enterprise Value
3.65B
Balance Sheet
Book Value Per Share
4.87
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
After Hours 0.2309 +0.0341 +17.33%
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
After Hours 2.67 -0.02 -0.74%
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
After Hours 0.33255 -0.00615 -1.82%
GERNGeron Corp1.5-0.06-3.85%-- 
After Hours 1.5092 +0.0092 +0.61%
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
After Hours 5.66 -0.33 -5.51%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.